–
Johnson & Johnson and its pharmaceutical group Janssen confirmed that Peru will be one of the locations of its phase 3 clinical study, to evaluate the effectiveness of its candidate vaccine against COVID-19.
The Ministry of Foreign Affairs indicated, through a statement, that the criteria considered by the company to define the clinical trial sites are the epidemiological profile of the countries, the conditions of their research infrastructure and the regulatory approval process.
In addition, he stressed that Peru, through close work with the company, has met the established requirements.
Currently, Phase 2 of the Johnson & Johnson clinical study is taking place in the United States and Belgium. It is expected that the results of this phase will be available in September, after which phase 3 would begin. The clinical study of this third phase will involve 60,000 volunteers from all over the world and whose ages would range between 18 and 60 years.
“The participation of Peruvian citizens will make it possible to contribute to international efforts to develop a safe and effective vaccine against COVID-19 that allows controlling the spread of the SARS-CoV-2 virus and reactivating economies”said the Foreign Ministry.
On August 20, President Martín Vizcarra announced that our country granted authorization to international laboratories to carry out clinical trials to test the effectiveness of vaccine candidates against COVID-19. In the case of Johnson & Johnson, clinical trials would begin on September 15.
– .
